Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Dec 16, 2025
Reporting period
Not applicable
Filed with the SEC
Dec 18, 2025
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001242615-25-000004
Filed / recorded
Dec 18, 2025, 11:39 PM UTC
Added to OQRO
Oct 6, 2026, 4:40 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
ARROWHEAD PHARMACEUTICALS, INC.
Issuer CIK
879407
Ticker
ARWR
Reporting person
Adeoye Y Olukotun
Relationship
Director
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Dec 16, 2025
Transaction code
A
Shares / units
7,819
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
43,600
Ownership form
Direct
Amendment
No
Footnotes from the filing
Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date.